BioXcel Therapeutics, Inc. (BTAI)
NASDAQ: BTAI · Real-Time Price · USD
0.566
-0.023 (-3.83%)
Nov 21, 2024, 12:13 PM EST - Market open
BioXcel Therapeutics Employees
BioXcel Therapeutics had 74 employees as of December 31, 2023. The number of employees decreased by 109 or -59.56% compared to the previous year.
Employees
74
Change (1Y)
-109
Growth (1Y)
-59.56%
Revenue / Employee
$30,757
Profits / Employee
-$959,405
Market Cap
23.04M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
DarioHealth | 294 |
Athira Pharma | 67 |
PolyPid | 62 |
Equillium | 44 |
Inspira Technologies Oxy B.H.N. | 42 |
GlycoMimetics | 35 |
Chemomab Therapeutics | 20 |
Lipocine | 17 |
BTAI News
- 7 days ago - BioXcel Therapeutics, Inc. (BTAI) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 13 days ago - BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024 - GlobeNewsWire
- 23 days ago - BioXcel Therapeutics to Present at ThinkEquity Conference - GlobeNewsWire
- 5 weeks ago - BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder - GlobeNewsWire
- 2 months ago - BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation - GlobeNewsWire
- 2 months ago - BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia - GlobeNewsWire
- 3 months ago - BioXcel Therapeutics, Inc. (BTAI) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 4 months ago - BioXcel Therapeutics Announces Preliminary Estimated Unaudited Second Quarter Net Revenues from Sales of IGALMI™ (dexmedetomidine) Sublingual Film - GlobeNewsWire